TEVA LABORATORIES UK LIMITED
Operating as the British subsidiary of the dual-listed Israeli multinational Teva Pharmaceutical Industries, the company manufactures and supplies generic, biosimilar, and branded medicines, including over-the-counter products like Sudocrem and Infacol, to the NHS and other healthcare providers.
Get an alert when TEVA LABORATORIES UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
—
Latest balance sheet
Net assets
£14M
-79.7% vs 2023
Employees
0
Average over period
Profit before tax
£54M
-35% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £23,672,000 | £8,887,000 | -62.5% | |
| Operating profit | £77,978,000 | £49,840,000 | -36.1% | |
| Profit before tax | £83,806,000 | £54,465,000 | -35% | |
| Net profit | £65,516,000 | £39,288,000 | -40% | |
| Cash | — | — | — | |
| Total assets less current liabilities | £67,974,000 | £13,817,000 | -79.7% | |
| Net assets | £67,974,000 | £13,817,000 | -79.7% | |
| Equity | £67,974,000 | £13,817,000 | -79.7% | |
| Average employees | 0 | 0 | — | |
| Wages | — | — | — | |
| Directors' remuneration | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | 114.7% | 360.7% | |
| Gearing (liabilities / total assets) | 32.4% | 73.8% | |
| Current ratio | 4.67x | 1.39x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- TEVA LABORATORIES UK LIMITED 2018-07-24 → present
- FOREST LABORATORIES UK LIMITED 2002-04-05 → 2018-07-24
- PHARMAX LIMITED 1954-05-03 → 2002-04-05
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors believe that preparing the financial statements on a going concern basis is appropriate due to the continued financial support of Teva Pharmaceuticals Europe B.V., a fellow group company. The directors have received confirmation from Teva Pharmaceuticals Europe B.V. that it has pledged its continuing support for a minimum of 12 months from the date of signing these financial statements.”
Significant events
- “During September 2024, the company completed the divestment of several intangible assets as part of a global strategic review by the Teva group to enhance its focus on core products.”
- “On 19 November 2024, the company paid a dividend of £94,000,000 to Teva Pharma Holdings Limited.”
- “The divestments made during 2023 and 2024 may lead to reduced revenues in 2025 and future years.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 17 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CHARLESWORTH, Stephen Michael | Director | 2020-04-29 | Feb 1967 | British |
| INNES, Kim | Director | 2016-10-01 | Aug 1968 | British |
Show 17 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| LIVINGSTONE, Andrew John Robertson | Secretary | 1998-04-01 | 2015-06-01 |
| MORE, William Jamieson | Secretary | — | 1998-03-31 |
| NELLIGAN, Tom | Secretary | 2015-06-01 | 2016-08-02 |
| PINSENT MASONS SECRETARIAL LIMITED | Corporate Secretary | 2017-03-13 | 2017-03-13 |
| BURKE, Diarmuid | Director | 1997-12-01 | 2015-03-30 |
| COOPER, Dean Michael | Director | 2018-07-12 | 2020-04-29 |
| DANIELL, Richard Gordon | Director | 2016-08-02 | 2016-10-01 |
| GOLDBERG, Anthony | Director | — | 1995-06-07 |
| HART, Richard William | Director | — | 1997-11-30 |
| JAKES, Nadine | Director | 2014-12-01 | 2016-08-02 |
| MCDONALD, Michael | Director | 2014-04-02 | 2015-03-30 |
| MORE, William Jamieson | Director | — | 1998-03-31 |
| SOLOMON, Howard | Director | — | 2014-03-31 |
| STAFFORD, Raymond Thomas | Director | — | 2014-04-02 |
| VINCENT, Sara Jayne | Director | 2014-12-01 | 2016-08-02 |
| WILLIAMS, Robert | Director | 2016-08-02 | 2018-06-27 |
| WORTH, John Christopher | Director | 1997-12-01 | 2006-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Teva Pharma Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-08-02 | Active |
Filing timeline
Last 20 of 140 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-17 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-10-06 | AA | accounts | Accounts with accounts type full | |
| 2024-12-16 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-09 | AA | accounts | Accounts with accounts type full | |
| 2023-12-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-07 | AA | accounts | Accounts with accounts type full | |
| 2023-01-03 | AA | accounts | Accounts with accounts type full | |
| 2022-12-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-01-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-10-03 | AA | accounts | Accounts with accounts type full | |
| 2020-12-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2020-11-09 | AA | accounts | Accounts with accounts type group | |
| 2020-04-29 | TM01 | officers | Termination director company with name termination date | |
| 2020-04-29 | AP01 | officers | Appoint person director company with name date | |
| 2019-12-13 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2019-10-10 | AA | accounts | Accounts with accounts type group | |
| 2019-09-30 | CH01 | officers | Change person director company with change date | |
| 2018-12-12 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2018-10-30 | AA | accounts | Accounts with accounts type group | |
| 2018-07-24 | AD01 | address | Change registered office address company with date old address new address |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.